 | Up a level |
Haber, Philipp K; Castet, Florian; Torres-Martin, Miguel; Andreu-Oller, Carmen; Puigvehí, Marc; Maeda, Miho; Radu, Pompilia; Dufour, Jean-Francois; Verslype, Chris; Czauderna, Carolin; Marquardt, Jens U; Galle, Peter R; Vogel, Arndt; Bathon, Melanie; Meyer, Tim; Labgaa, Ismail; Digklia, Antonia; Roberts, Lewis R; Mohamed Ali, Mohamed A; Mínguez, Beatriz; ... (2023). Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. Gastroenterology, 164(1), 72-88.e18. Elsevier 10.1053/j.gastro.2022.09.005
Gallon, John; Coto-Llerena, Mairene; Ercan, Caner; Bianco, Gaia; Paradiso, Viola; Nuciforo, Sandro; Taha-Melitz, Stephanie; Meier, Marie-Anne; Boldanova, Tujana; Pérez-Del-Pulgar, Sofía; Rodríguez-Tajes, Sergio; von Flüe, Markus; Soysal, Savas D; Kollmar, Otto; Llovet, Josep M; Villanueva, Augusto; Terracciano, Luigi M; Heim, Markus H; Ng, Charlotte K. Y. and Piscuoglio, Salvatore (2022). Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Molecular oncology, 16(3), pp. 665-682. Wiley 10.1002/1878-0261.13154
Llovet, Josep M; Villanueva, Augusto; Lachenmayer, Anja; Finn, Richard S (2015). Erratum for Advances in targeted therapies for hepatocellular carcinoma in the genomic era. [Nat Rev Clin Oncol. 2015]. Nature reviews - clinical oncology, 12(8), p. 436. Nature Publishing Group 10.1038/nrclinonc.2015.121
Llovet, Josep M; Villanueva, Augusto; Lachenmayer, Anja; Finn, Richard S (2015). Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nature reviews - clinical oncology, 12(7), pp. 408-424. Nature Publishing Group 10.1038/nrclinonc.2015.103
